AbelZeta updated clinical results from the first-in-human study investigating C-CAR031 (now known as AZD7003), a novel glypican-3 (GPC3)-targeted armored CAR-T in advanced hepatocellular carcinoma (HCC), presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The post AbelZeta announces updated clinical results for C-CAR031 (AZD7003), a GPC3-targeted armored autologous CAR-T in advanced hepatocellular carcinoma at ESMO Congress 2026 appeared first on AbelZeta .